Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease
- PMID: 2529544
- PMCID: PMC298116
- DOI: 10.1073/pnas.86.19.7611
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease
Abstract
Interleukin 1, an immune response-generated cytokine that stimulates astrocyte proliferation and reactivity (astrogliosis), was present in up to 30 times as many glial cells in tissue sections of brain from patients with Down syndrome and Alzheimer disease compared with age-matched control subjects. Most interleukin 1-immunoreactive glia in Down syndrome and Alzheimer disease were classified as microglia. The number of interleukin 1 immunoreactive neurons did not appear to differ in Down syndrome and Alzheimer disease compared with control brain. Numerous temporal lobe astrocytes in Alzheimer disease and postnatal Down syndrome were intensely interleukin 1-, S-100-, and glial fibrillary acidic protein-immunoreactive and had reactive structure. Interleukin 1 levels in Alzheimer disease temporal lobe homogenates were elevated, as were the levels of S-100 and glial fibrillary acidic protein, two proteins reportedly elevated in reactive astrocytes. These data suggest that increased expression of S-100 in Down syndrome, resulting from duplication of the gene on chromosome 21 that encodes the beta subunit of S-100, may be augmented by elevation of interleukin 1. As a corollary, the astrogliosis in Alzheimer disease may be promoted by elevation of interleukin 1.
Similar articles
-
Developmental changes of S-100 protein and glial fibrillary acidic protein in the brain in Down syndrome.Exp Neurol. 1993 Apr;120(2):170-6. doi: 10.1006/exnr.1993.1052. Exp Neurol. 1993. PMID: 8491278
-
Neuronal plasticity and astrocytic reaction in Down syndrome and Alzheimer disease.J Neurol Sci. 1990 Aug;98(1):63-79. doi: 10.1016/0022-510x(90)90182-m. J Neurol Sci. 1990. PMID: 1977892
-
S100 beta protein expression in Alzheimer disease: potential role in the pathogenesis of neuritic plaques.J Neurosci Res. 1994 Nov 1;39(4):398-404. doi: 10.1002/jnr.490390406. J Neurosci Res. 1994. PMID: 7884819
-
Growth and development of the brain in Down syndrome.Prog Clin Biol Res. 1991;373:133-52. Prog Clin Biol Res. 1991. PMID: 1838182 Review.
-
Trisomy 21 and the brain.J Neuropathol Exp Neurol. 2004 Jul;63(7):679-85. doi: 10.1093/jnen/63.7.679. J Neuropathol Exp Neurol. 2004. PMID: 15290893 Free PMC article. Review.
Cited by
-
Astroglial Vesicular Trafficking in Neurodegenerative Diseases.Neurochem Res. 2017 Mar;42(3):905-917. doi: 10.1007/s11064-016-2055-1. Epub 2016 Sep 14. Neurochem Res. 2017. PMID: 27628292
-
The immune system and developmental programming of brain and behavior.Front Neuroendocrinol. 2012 Aug;33(3):267-86. doi: 10.1016/j.yfrne.2012.08.006. Epub 2012 Sep 9. Front Neuroendocrinol. 2012. PMID: 22982535 Free PMC article. Review.
-
Neurobiochemical Cross-talk Between COVID-19 and Alzheimer's Disease.Mol Neurobiol. 2021 Mar;58(3):1017-1023. doi: 10.1007/s12035-020-02177-w. Epub 2020 Oct 19. Mol Neurobiol. 2021. PMID: 33078369 Free PMC article. Review.
-
A change of PD-1/PD-L1 expression on peripheral T cell subsets correlates with the different stages of Alzheimer's Disease.Cell Biosci. 2022 Sep 30;12(1):162. doi: 10.1186/s13578-022-00897-1. Cell Biosci. 2022. PMID: 36180897 Free PMC article.
-
The contribution of the citrate pathway to oxidative stress in Down syndrome.Immunology. 2016 Dec;149(4):423-431. doi: 10.1111/imm.12659. Epub 2016 Oct 3. Immunology. 2016. PMID: 27502741 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials